Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Clinical Oncology 2, 80–81 (1 February 2005) | doi:10.1038/ncponc0079
Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Abstract
Fountzilas G et al. (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology 15: 1517–1526 Synopsis Background The combination of paclitaxel and doxorubicin is effective in advanced breast cancer, but epirubicin has been substituted for doxorubicin because it reduces cardiotoxicity.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
